APTX   $0.2357  1.68% Market Closed

Aptinyx Inc
Last Events:

2023-03-29 Trend pattern changed from нисходящий треугольник to симметричный треугольник.

2023-03-29 Trend pattern changed from симметричный треугольник to нисходящий треугольник.

2023-03-28 Trend pattern changed from нисходящий треугольник to симметричный треугольник.

2023-03-28 Trend pattern changed from симметричный треугольник to нисходящий треугольник.

2023-03-27 Trend pattern changed from нисходящий треугольник to симметричный треугольник.

2023-03-27 Trend pattern changed from симметричный треугольник to нисходящий треугольник.

2023-03-26 Trend pattern changed from нисходящий треугольник to симметричный треугольник.

2023-03-26 Trend pattern changed from симметричный треугольник to нисходящий треугольник.


Current temperature: 1.50
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 0.17
Target: 2.25
High with 48% probability: 0.74
Analyst Recommendations:
Number of estimates 4
Target Price Mean 2.25
Mean unverified/preliminary 2.25 / 2.25
Target Price Low / High 1.00 / 4.00
Median / STD DEV 2.00 / 1.26
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd Sell Sell Sell
stoch Sell Sell -
ma20 Sell - -
ma50 Sell - -
ma100 Sell - -
Candlestick PatternMarch 15, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US03836N1037
ceo Dr. Andrew D. Kidd B.M. B.Ch., M.D.
Website https://www.aptinyx.com
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.